FDA Expands Enhertu Indication to HER2-Positive Solid Tumors FDA Expands Enhertu Indication to HER2-Positive Solid Tumors

The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news